Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

05. September 2018 07:00 ET | Quelle: Recro Pharma, Inc.

Recro Pharma to Present IV Meloxicam Data at PAINWeek® 2018

MALVERN, Pa., Sept. 05, 2018 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (NASDAQ:REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for the hospital and other acute care...
04. September 2018 07:00 ET | Quelle: Recro Pharma, Inc.

Recro Pharma Provides Regulatory Update for IV Meloxicam

MALVERN, Pa., Sept. 04, 2018 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for the hospital and other acute care...
07. August 2018 07:00 ET | Quelle: Recro Pharma, Inc.

Recro Pharma Reports Second Quarter 2018 Financial Results

MALVERN, Pa., Aug. 07, 2018 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (NASDAQ:REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for the hospital and other acute care...
31. Juli 2018 07:00 ET | Quelle: Recro Pharma, Inc.

Recro Pharma to Report Second Quarter 2018 Financial Results and Host Conference Call and Webcast on August 7, 2018

MALVERN, Pa., July 31, 2018 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (NASDAQ:REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for the hospital and other acute care...
26. Juni 2018 07:00 ET | Quelle: Recro Pharma, Inc.

Recro Pharma Announces Publication of Phase III IV Meloxicam Abdominoplasty Data in Plastic and Reconstructive Surgery Global Open Journal

MALVERN, Pa., June 26, 2018 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (NASDAQ:REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for the hospital and other acute care...
24. Mai 2018 07:00 ET | Quelle: Recro Pharma, Inc.

Recro Pharma Receives Complete Response Letter from the FDA

MALVERN, Penn., May 24, 2018 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for the hospital and other acute care...
09. Mai 2018 07:00 ET | Quelle: Recro Pharma, Inc.

Recro Pharma Reports First Quarter 2018 Financial Results

Upcoming May 26, 2018 PDUFA Date for IV Meloxicam Company to Host Conference Call Today at 8:00 AM ET MALVERN, Pa., May 09, 2018 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (NASDAQ:REPH), a revenue...
07. Mai 2018 07:00 ET | Quelle: Recro Pharma, Inc.

Recro Pharma Announces Receipt of Issue Notifications for Three New Patents for IV Meloxicam

MALVERN, Pa., May 07, 2018 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for the hospital and other acute care...
02. Mai 2018 16:05 ET | Quelle: Recro Pharma, Inc.

Recro Pharma Announces Commercial Team Additions

MALVERN, Pa., May 02, 2018 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for the hospital and other acute care...
02. Mai 2018 07:00 ET | Quelle: Recro Pharma, Inc.

Recro Pharma to Report First Quarter 2018 Financial Results and Host Conference Call and Webcast on May 9, 2018

Conference Call and Webcast Scheduled for Wednesday, May 9, 2018 at 8:00 a.m. ET MALVERN, Pa., May 02, 2018 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (NASDAQ:REPH), a revenue generating specialty...

Vorherige Seite